Kartik Sehgal

9.7k total citations
50 papers, 765 citations indexed

About

Kartik Sehgal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kartik Sehgal has authored 50 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Kartik Sehgal's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (8 papers). Kartik Sehgal is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (8 papers). Kartik Sehgal collaborates with scholars based in United States, United Kingdom and Switzerland. Kartik Sehgal's co-authors include Daniel B. Costa, Kavita M. Dhodapkar, Madhav V. Dhodapkar, Deepa Rangachari, Deepa Rangachari, Meghan Shea, Paul A. VanderLaan, Ritu R. Gill, Hollis Viray and Page Widick and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kartik Sehgal

47 papers receiving 755 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kartik Sehgal United States	15	388	235	222	184	99	50	765
Tongyu Lin China	17	484 1.2×	216 0.9×	139 0.6×	168 0.9×	51 0.5×	71	1.1k
Georg Pall Austria	17	362 0.9×	161 0.7×	195 0.9×	166 0.9×	66 0.7×	49	811
Deok‐Hwan Yang South Korea	20	437 1.1×	256 1.1×	144 0.6×	279 1.5×	488 4.9×	124	1.3k
Alfonso Berrocal Spain	17	399 1.0×	213 0.9×	123 0.6×	115 0.6×	16 0.2×	60	681
Rajnish Nagarkar India	12	246 0.6×	141 0.6×	132 0.6×	173 0.9×	21 0.2×	61	665
Laura Cattaneo Italy	15	633 1.6×	228 1.0×	141 0.6×	294 1.6×	67 0.7×	57	1.0k
Ching‐Chan Lin Taiwan	13	135 0.3×	203 0.9×	88 0.4×	44 0.2×	92 0.9×	32	481
Rajive Kumar India	19	146 0.4×	351 1.5×	86 0.4×	163 0.9×	328 3.3×	96	973
Katie Meehan Australia	20	151 0.4×	518 2.2×	122 0.5×	355 1.9×	46 0.5×	51	1.1k
Debora Martorelli Italy	20	564 1.5×	186 0.8×	122 0.5×	369 2.0×	20 0.2×	34	989

Countries citing papers authored by Kartik Sehgal

Since Specialization

Citations

This map shows the geographic impact of Kartik Sehgal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kartik Sehgal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kartik Sehgal more than expected).

Fields of papers citing papers by Kartik Sehgal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kartik Sehgal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kartik Sehgal. The network helps show where Kartik Sehgal may publish in the future.

Co-authorship network of co-authors of Kartik Sehgal

This figure shows the co-authorship network connecting the top 25 collaborators of Kartik Sehgal. A scholar is included among the top collaborators of Kartik Sehgal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kartik Sehgal. Kartik Sehgal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sehgal, Kartik, Jesús Corral Jaime, Steven Powell, et al.. (2025). Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).. Journal of Clinical Oncology. 43(16_suppl). 3010–3010. 1 indexed citations

Hanna, Glenn J., Michael J. Dennis, Rosh K.V. Sethi, et al.. (2024). Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 30(15). 3329–3336. 21 indexed citations

Sang, Ye, Mengke Chen, Shubin Hong, et al.. (2024). The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells. Translational Oncology. 45. 101991–101991. 6 indexed citations

Wang, Judy S., David Sommerhalder, Manish Sharma, et al.. (2024). Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.. Journal of Clinical Oncology. 42(16_suppl). 2582–2582. 2 indexed citations

Peters, Solange, Antoine Hollebecque, Kartik Sehgal, et al.. (2024). Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).. Journal of Clinical Oncology. 42(16_suppl). 8521–8521. 3 indexed citations

Hanna, Glenn J., Michael J. Dennis, Rosh K.V. Sethi, et al.. (2024). Personalized circulating tumor (ct)DNA for monitoring disease status in HPV-negative head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 6056–6056. 1 indexed citations

Zhang, Ze, Kartik Sehgal, Keisuke Shirai, et al.. (2024). Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy. npj Precision Oncology. 8(1). 267–267. 1 indexed citations

Gunturu, Krishna S., Hollis Viray, Andrew J. Piper‐Vallillo, et al.. (2024). Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer. 198. 108023–108023. 1 indexed citations

Rettig, Eleni M., Jonathan D. Schoenfeld, Janice Μ. Miller, et al.. (2024). A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA. Clinical Cancer Research. 31(9). 1605–1614. 8 indexed citations

10.

Zhang, Ze, Kartik Sehgal, Rondi A. Butler, et al.. (2024). Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors. Epigenomics. 16(11-12). 799–807. 2 indexed citations

11.

Dennis, Michael J., Dean C. Pavlick, Alec Kacew, et al.. (2024). Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma. Journal of Translational Medicine. 22(1). 960–960. 2 indexed citations

12.

Hanna, Glenn J., Anne O’Neill, Kartik Sehgal, et al.. (2024). Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 6031–6031. 1 indexed citations

13.

Rettig, Eleni M., J. Miller, Elizabeth J. Carey, et al.. (2024). Prospective Study of Plasma Biomarker-Guided Surveillance of HPV-positive Oropharynx Cancer Using TTMV-HPV DNA: The SPHERE Study. International Journal of Radiation Oncology*Biology*Physics. 118(5). e50–e50. 2 indexed citations

14.

Bikas, Athanasios, Sara Ahmadi, Θεοδώρα Παππά, et al.. (2023). Additional Oncogenic Alterations in RAS -Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes. Clinical Cancer Research. 29(14). 2678–2685. 16 indexed citations

15.

Sehgal, Kartik, Ze Zhang, Keisuke Shirai, et al.. (2023). Peripheral blood epigenetic immune-profiling and survival outcomes with anti-programmed death (PD)-1 based therapy in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).. Journal of Clinical Oncology. 41(16_suppl). 6062–6062.

16.

Spira, Alexander I., Michael S. Gordon, Jason T. Henry, et al.. (2023). 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors. SHILAP Revista de lepidopterología. A852–A852. 1 indexed citations

17.

Hollebecque, Antoine, Juanita Lopez, Sarina A. Piha‐Paul, et al.. (2023). SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).. Journal of Clinical Oncology. 41(16_suppl). 3024–3024. 7 indexed citations

18.

Hollebecque, Antoine, Juanita Lopez, Sarina A. Piha‐Paul, et al.. (2022). 731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001). Regular and Young Investigator Award Abstracts. A763–A763. 2 indexed citations

19.

Ahrendsen, Jared T., Kartik Sehgal, Sasmit Sarangi, et al.. (2021). Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma. Journal of Hematology. 10(5). 212–216. 5 indexed citations

20.

Sehgal, Kartik, Kavita M. Dhodapkar, & Madhav V. Dhodapkar. (2014). Targeting human dendritic cells in situ to improve vaccines. Immunology Letters. 162(1). 59–67. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact